Atlantic-Pacific Capital Announces Final Close on
$701 Million Oversubcribed Drug Royalty II Fund
April 07, 2010 08:33 AM Eastern Daylight Time
GREENWICH, Conn.--(EON: Enhanced Online News)--Atlantic-Pacific Capital, a leading independent global
placement agent, announced today the final closing of Drug Royalty II (the “Fund”) with $701 million of equity
capital commitments. The Fund, managed by DRI Capital, had an initial target of $500 million and received
tremendous support from a broad group of institutional investors across the U.S., Canada, Europe, Australia and
Asia. Atlantic-Pacific Capital acted as the exclusive global placement agent and advisor.
“DRI is one of the leading firms with a long-running tenure in the royalty monetization space. Its differentiated
business model proved to be a unique portfolio diversifier for Limited Partners,” explained Alex Leykikh, Partner at
“While we managed our core business, Atlantic-Pacific Capital assisted us with every facet of the fundraising
process, which they performed with thoughtfulness, professionalism and integrity,” said Behzad Khosrowshahi, DRI
Capital’s President and CEO.
Based in Toronto, DRI Capital is a healthcare industry-focused investment management firm with over $2.0 billion
under management that acquires royalties from pharmaceutical and biotechnology companies, research institutes,
universities and inventors. The Fund’s investment team has over 100 years of combined experience in the healthcare
industry, including the identification, assessment and management of royalty streams. DRI Capital raised $240 million
of equity capital for Drug Royalty I in 2006.
“We congratulate the DRI team on this successful global fundraise in light of the current challenging capital-raising
environment,” added James Weidner, Partner at Atlantic-Pacific Capital.
Atlantic-Pacific Capital, Inc. (www.apcap.com)
With offices in New York, Greenwich, Chicago, San Francisco, London and Hong Kong, Atlantic-Pacific